Search Results

You are looking at 91 - 100 of 107 items for :

  • "aromatase inhibitor" x
  • User-accessible content x
Clear All
Full access

Yuan-Yuan Lei, Suzanne C. Ho, Ashley Cheng, Carol Kwok, Chi-Kiu Iris Lee, Ka Li Cheung, Roselle Lee, Herbert H.F. Loong, Yi-Qian He, and Winnie Yeo

-conserving surgery, chemotherapy, radiation therapy, hormone therapy such as tamoxifen and aromatase inhibitors, and anti-HER2 therapy). At baseline and 18-month follow-up, the self-reported total comorbidity counts included diabetes, hypertension, hyperlipidemia

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar, and Dorothy A. Shead

women) or an aromatase inhibitor (for postmenopausal women, especially those under 60 years of age or those with concerns of embolism), may be considered as a strategy to reduce the risk of ipsilateral breast cancer recurrence in women with ER

Full access

Adrienne G. Waks and Ann H. Partridge

. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer . J Clin Oncol 2015 ; 33 : 2424 – 2429 . 3. Shapira M Raanani H Meirow D . IVF for fertility preservation

Full access

Jill R. Tichy, Elgene Lim, and Carey K. Anders

the metastatic setting. 43 Once deemed physiologically postmenopausal or in the presence of biochemical menopause, treatment with an aromatase inhibitor and/or fulvestrant may be indicated. Notably, a small phase II study of anastrozole and goserelin

Full access

Kari E. Hacker, Shitanshu Uppal, and Carolyn Johnston

, similar to those seen with aromatase inhibitor therapy, with the use of the oral MEK1/2 inhibitor selumetinib, such that 15% and 65% of patients had an objective clinical response and stable disease, respectively. 82 Several questions remain, including

Full access

Jessica K. DeMartino

,N0,M0, or stage II or III hormone receptor-negative breast cancer. NQF #0220: Tamoxifen or third-generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c,N0,M0, or stage II or III

Full access

Philip J. Saylor and Matthew R. Smith

in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer . J Clin Oncol 2008 ; 26 : 4875 – 4882 . 75. Lewiecki EM Miller PD McClung MR . Two-year treatment with denosumab (AMG 162

Full access

Rashmi Chugh

treated with an aromatase inhibitor yielded a median time to progression of 6 months. 89 Studies of new therapies that block the estrogen signaling pathway show this is a reasonable strategy for treating patients with chondrosarcoma. In vitro studies

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

status. One percent of breast cancers occur in men, 1 and men with breast cancer should be treated similarly to postmenopausal women, except that the use of aromatase inhibitors is ineffective without concomitant suppression of testicular steroidogenesis

Full access

fulvestrant was 11.7%, 8.8%, 7.6%, and 6.5%). Conclusions: Among postmenopausal women with HR + /HER2 − mBC, approximately two-thirds of patients received first-line ET. Although nonsteroidal aromatase inhibitors (NSAIs; anastrozole or letrozole) may be